| Symbol | ARGX |
|---|---|
| Name | ARGENX SE |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | WILLEMSTRAAT 5, BREDA, 4811 AH, Netherlands |
| Telephone | +31 763030488 |
| Fax | — |
| — | |
| Website | https://www.argenx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-111, ARGX-109, ARGX-115, ARGX-112, and others. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Switzerland. Additional info from NASDAQ: |
2026-04-18 05:00
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
Read more
2026-04-18 05:00
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
Read more
2026-03-06 06:00
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
Read more
2026-03-06 06:00
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04777734 | Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammator… | — | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Available | — | — | ClinicalTrials.gov |
| NCT07294170 | ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and … | — | Myasthenia Gravis | Recruiting | 2025-12-19 | 2028-03-07 | ClinicalTrials.gov |
| NCT07287982 | A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Imm… | Phase2 | Spinal Muscular Atrophy (SMA) | Recruiting | 2025-12-19 | 2029-05-28 | ClinicalTrials.gov |
| NCT07284420 | ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy… | Phase2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | Recruiting | 2025-12-19 | 2028-03-07 | ClinicalTrials.gov |
| NCT07194850 | A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years … | Phase2 | Immune Thrombocytopenia (ITP) | Recruiting | 2025-10-20 | 2030-10-01 | ClinicalTrials.gov |
| NCT07011589 | Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VY… | Phase1 | Epidermolysis Bullosa (EB) | Not_Yet_Recruiting | 2025-07-01 | 2026-10-01 | ClinicalTrials.gov |
| NCT06968338 | A Study to Assess the Safety of ARGX-213 in Healthy Volunteers | Phase1 | Healthy Volunteers | Completed | 2025-04-11 | 2026-03-20 | ClinicalTrials.gov |
| NCT06799416 | A Study to Assess the Safety of ARGX-109 in Healthy Volunteers | Phase1 | Healthy Volunteer | Completed | 2025-01-14 | 2025-08-08 | ClinicalTrials.gov |
| NCT06742190 | A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adult… | Phase3 | Multifocal Motor Neuropathy (MMN) | Recruiting | 2024-12-18 | 2029-12-01 | ClinicalTrials.gov |
| NCT06655155 | A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults Wit… | Phase2 | Systemic Sclerosis (SSc) | Recruiting | 2024-11-11 | 2027-09-01 | ClinicalTrials.gov |
| NCT06298565 | A Non-interventional, Post-authorisation Safety Study of Patients Treated With … | — | Myasthenia Gravis | Recruiting | 2024-11-04 | 2034-06-01 | ClinicalTrials.gov |
| NCT06436742 | A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Pa… | Phase1 | Congenital Myasthenic Syndrome | Recruiting | 2024-09-24 | 2028-01-24 | ClinicalTrials.gov |
| NCT06298552 | A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patie… | Phase3 | Generalized Myasthenia Gravis | Active_Not_Recruiting | 2024-04-16 | 2027-06-01 | ClinicalTrials.gov |
| NCT06307613 | A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyro… | Phase3 | Thyroid Eye Disease | Terminated | 2024-03-27 | 2026-02-12 | ClinicalTrials.gov |
| NCT06078553 | A Natural History Study in Participants With Congenital Myasthenic Syndromes (C… | — | Congenital Myasthenic Syndrome | Recruiting | 2024-02-13 | 2027-06-01 | ClinicalTrials.gov |
| NCT06203457 | Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Pati… | Phase2 | Primary Sjögren's Syndrome | Completed | 2023-11-29 | 2025-02-03 | ClinicalTrials.gov |
| NCT05927415 | A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgar… | Phase1 | Renal Impairment | Completed | 2023-07-17 | 2024-06-12 | ClinicalTrials.gov |
| NCT04812925 | A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcut… | Phase3 | Primary Immune Thrombocytopenia | Active_Not_Recruiting | 2021-11-17 | 2026-10-01 | ClinicalTrials.gov |
| NCT04833894 | Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod A… | Phase2 | Generalized Myasthenia Gravis | Recruiting | 2021-10-26 | 2027-03-01 | ClinicalTrials.gov |
| NCT04598477 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulati… | Phase3 | Pemphigus Vulgaris | Terminated | 2021-07-15 | 2024-03-25 | ClinicalTrials.gov |
| NCT04264806 | A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidin… | Phase2 | Myelodysplastic Syndromes | Withdrawn | 2021-05-06 | 2025-01-28 | ClinicalTrials.gov |
| NCT04735432 | Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administe… | Phase3 | Generalized Myasthenia Gravis | Completed | 2021-02-05 | 2021-12-13 | ClinicalTrials.gov |
| NCT04241549 | A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Dia… | Phase1 | Leukemia, Myeloid, Acute | Completed | 2020-03-25 | 2021-07-19 | ClinicalTrials.gov |
| NCT04150887 | Cusatuzumab in Combination With Background Therapy for the Treatment of Partici… | Phase1 | Leukemia, Myeloid, Acute | Active_Not_Recruiting | 2019-12-23 | 2026-05-15 | ClinicalTrials.gov |
| NCT03770403 | A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis … | Phase3 | Generalized Myasthenia Gravis | Completed | 2019-03-01 | 2022-06-30 | ClinicalTrials.gov |
| NCT02965573 | A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in P… | Phase2 | Myasthenia Gravis | Completed | 2016-12-30 | 2017-10-20 | ClinicalTrials.gov |
| NCT03030612 | A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly … | Phase1 | Leukemia, Myeloid, Acute | Completed | 2016-12-01 | 2022-08-01 | ClinicalTrials.gov |
| NCT02055066 | A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer. | Phase1 | Cancer | Completed | 2014-01-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01813539 | A Study of ARGX-110 in Participants With Advanced Malignancies | Phase1 | Neoplasms | Completed | 2013-02-27 | 2020-07-10 | ClinicalTrials.gov |
Total clinical trials: 29
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| ARGX-213 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Placebo PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | RECRUITING | NCT07264426 |
| Efgartigimod IV or Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION | NCT05374590 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| ARGX-213 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Placebo PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | RECRUITING | NCT07264426 |
| Efgartigimod IV or Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION | NCT05374590 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| ARGX-213 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| Efgartigimod IV or Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION | NCT05374590 |
| Placebo PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | RECRUITING | NCT07264426 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| ARGX-213 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| Efgartigimod IV or Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION | NCT05374590 |
| Placebo PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | RECRUITING | NCT07264426 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| ARGX-213 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| Efgartigimod IV or Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION | NCT05374590 |
| Placebo PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | RECRUITING | NCT07264426 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| ARGX-213 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| Efgartigimod IV or Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION | NCT05374590 |
| Placebo PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | RECRUITING | NCT07264426 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| ARGX-213 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| Efgartigimod IV or Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION | NCT05374590 |
| Placebo PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | RECRUITING | NCT07264426 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| ARGX-213 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| Efgartigimod IV or Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION | NCT05374590 |
| Placebo PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | RECRUITING | NCT07264426 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| ARGX-213 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| Efgartigimod IV or Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION | NCT05374590 |
| Placebo PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | RECRUITING | NCT07264426 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| ARGX-213 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06968338 |
| Efgartigimod IV or Efgartigimod PH20 SC | Other | Phase PHASE2 | Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION | NCT05374590 |
| Placebo PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE2 | Systemic Sclerosis (SSc) | RECRUITING | NCT06655155 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | RECRUITING | NCT07264426 |
| Placebo IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| ARGX-119 IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Myositis | ENROLLING_BY_INVITATION | NCT05979441 |
| Efgartigimod PH20 SC | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | RECRUITING | NCT07264426 |
| Placebo IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| ARGX-119 IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| Empasiprubart IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Efgartigimod IV | Other | Preclinical | Myasthenia Gravis | RECRUITING | NCT07294170 |
| Placebo | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| ARGX-119 | Other | Phase PHASE1 | Congenital Myasthenic Syndrome | RECRUITING | NCT06436742 |
| Empasiprubart IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Efgartigimod IV | Other | Phase PHASE2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING | NCT07284420 |
| Placebo IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| ARGX-119 IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| Placebo IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| ARGX-119 IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| Placebo IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| ARGX-119 IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| Placebo IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| ARGX-119 IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| Placebo IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| ARGX-119 IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| Placebo IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| ARGX-119 IV | Other | Phase PHASE2 | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT07287982 |
| Placebo PH20 SC | Other | Phase PHASE3 | Primary Sjogrens Disease | ACTIVE_NOT_RECRUITING | NCT06684847 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Primary Sjogrens Disease | ACTIVE_NOT_RECRUITING | NCT06684847 |
| Placebo PH20 SC | Other | Phase PHASE3 | Primary Sjogrens Disease | ACTIVE_NOT_RECRUITING | NCT06684847 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Primary Sjogrens Disease | ACTIVE_NOT_RECRUITING | NCT06684847 |
| Placebo PH20 SC | Other | Phase PHASE3 | Primary Sjogrens Disease | ACTIVE_NOT_RECRUITING | NCT06684847 |
| Efgartigimod PH20 SC | Other | Phase PHASE3 | Primary Sjogrens Disease | ACTIVE_NOT_RECRUITING | NCT06684847 |
| ARGX-119 | BIOLOGICAL | Phase PHASE2 | Amyotrophic Lateral Sclerosis | ACTIVE_NOT_RECRUITING | NCT06441682 |
| Placebo | OTHER | Phase PHASE2 | Amyotrophic Lateral Sclerosis | ACTIVE_NOT_RECRUITING | NCT06441682 |
Total products: 162